These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 28815277)

  • 1. Discontinuation rate and adverse events after 1 year of vaginal pessary use in women with pelvic organ prolapse.
    Yimphong T; Temtanakitpaisan T; Buppasiri P; Chongsomchai C; Kanchaiyaphum S
    Int Urogynecol J; 2018 Aug; 29(8):1123-1128. PubMed ID: 28815277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of pessary use in women aged 65 - 74 versus 75 years and older with pelvic organ prolapse: a 12-year study.
    Ramsay S; Tu le M; Tannenbaum C
    Int Urogynecol J; 2016 Aug; 27(8):1201-7. PubMed ID: 26872647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Affecting Successfulness of Vaginal Pessary Use for the Treatment of Pelvic Organ Prolapse.
    Lekskulchai O; Wanichsetakul P
    J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S115-20. PubMed ID: 26387398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term adherence to pessary use in women with pelvic organ prolapse: A retrospective cohort study.
    Koch M; Carlin G; Lange S; Umek W; Krall C; Bodner-Adler B
    Maturitas; 2023 Dec; 178():107828. PubMed ID: 37659128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors for dislodgment of vaginal pessary within one year in women with pelvic organ prolapse.
    Cheung RYK; Lee LLL; Chung TKH; Chan SSC
    Maturitas; 2018 Feb; 108():53-57. PubMed ID: 29290215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ring pessary for all pelvic organ prolapse.
    Manchana T
    Arch Gynecol Obstet; 2011 Aug; 284(2):391-5. PubMed ID: 20848116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a continuous-use ring-shaped vaginal pessary without support for advanced pelvic organ prolapse in postmenopausal women.
    Dueñas JL; Miceli A
    Int Urogynecol J; 2018 Nov; 29(11):1629-1636. PubMed ID: 29478114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term continuations rate of ring pessary use for symptomatic pelvic organ prolapse.
    Manchana T
    Arch Gynecol Obstet; 2024 May; 309(5):2203-2209. PubMed ID: 38189963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which factors should be considered in choosing pessary type and size for pelvic organ prolapse patients in a fitting trial?
    Ding J; Song XC; Deng M; Zhu L
    Int Urogynecol J; 2016 Dec; 27(12):1867-1871. PubMed ID: 27260324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pessary types and discontinuation rates in patients with advanced pelvic organ prolapse.
    Wolff B; Williams K; Winkler A; Lind L; Shalom D
    Int Urogynecol J; 2017 Jul; 28(7):993-997. PubMed ID: 27942793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Compliance of Self-Care Pessary in Symptomatic Pelvic Organ Prolapse.
    Charoenloet N; Srisukho S; Phongnarisorn C; Tongsong T; Rujijanakul Y
    Int Urogynecol J; 2024 Jun; 35(6):1263-1269. PubMed ID: 38748222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levator ani muscle avulsion is a risk factor for expulsion within 1 year of vaginal pessary placed for pelvic organ prolapse.
    Cheung RYK; Lee JHS; Lee LL; Chung TKH; Chan SSC
    Ultrasound Obstet Gynecol; 2017 Dec; 50(6):776-780. PubMed ID: 28078670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal ring pessary use for pelvic organ prolapse: continuation rates and predictors of continued use.
    Manonai J; Sarit-Apirak S; Udomsubpayakul U
    Menopause; 2018 Dec; 26(6):665-669. PubMed ID: 30562318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of pelvic organ prolapse and discontinuation of pessary treatment.
    Umachanger JK; Marcussen ML; Bøggild H; Kjærgaard N; Glavind K
    Int Urogynecol J; 2020 Sep; 31(9):1813-1819. PubMed ID: 32447418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vaginal estrogen on pessary use.
    Dessie SG; Armstrong K; Modest AM; Hacker MR; Hota LS
    Int Urogynecol J; 2016 Sep; 27(9):1423-9. PubMed ID: 26992727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 5-year prospective study of vaginal pessary use for pelvic organ prolapse.
    Lone F; Thakar R; Sultan AH; Karamalis G
    Int J Gynaecol Obstet; 2011 Jul; 114(1):56-9. PubMed ID: 21575953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcomes of Self-Management Gellhorn Pessary for Symptomatic Pelvic Organ Prolapse.
    Chien CW; Lo TS; Tseng LH; Lin YH; Hsieh WC; Lee SJ
    Female Pelvic Med Reconstr Surg; 2020 Nov; 26(11):e47-e53. PubMed ID: 31393340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defecatory dysfunction and other clinical variables are predictors of pessary discontinuation.
    Dengler EG; Mounsey LA; Gines F; Agha M; Long T; Geller EJ
    Int Urogynecol J; 2019 Jul; 30(7):1111-1116. PubMed ID: 30343377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial.
    Cheung RY; Lee JH; Lee LL; Chung TK; Chan SS
    Obstet Gynecol; 2016 Jul; 128(1):73-80. PubMed ID: 27275798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to support pessary in the treatment of pelvic organ prolapse: a retrospective study conducted among 1,371 women.
    Brandt CH; Yamolaei M; Wu C; Hansen UD; Rasch V
    Int Urogynecol J; 2024 Jan; 35(1):69-75. PubMed ID: 37548745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.